76D Stock Overview

Operates as a biopharmaceutical company. More details

76D fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Negative shareholders equity

Does not have a meaningful market cap (€2M)

Makes less than USD$1m in revenue (€64K)

Earnings have declined by 26% per year over past 5 years

+ 2 more risks

My Notes

Capture your thoughts, links and company narrative

Medesis Pharma S.A. Competitors

co.don

XTRA:CNW

€6.5m

Sangui Biotech International

HMSE:SBH

€419.8k

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Epigenomics

DB:ECX

€980.2k

Price History & Performance

Summary of share price highs, lows and changes for Medesis Pharma
Historical stock prices
Current Share Price	€0.26
52 Week High	€1.80
52 Week Low	€0.23
Beta	0.061
1 Month Change	-3.70%
3 Month Change	-13.33%
1 Year Change	-67.09%
3 Year Change	-94.97%
5 Year Change	n/a
Change since IPO	-97.56%

Recent updates

Shareholder Returns

	76D	DE Biotechs	DE Market
7D	10.6%	2.5%	-0.4%
1Y	-67.1%	-10.2%	7.9%

Return vs Industry: 76D underperformed the German Biotechs industry which returned -10.2% over the past year.

Return vs Market: 76D underperformed the German Market which returned 7.9% over the past year.

Price Volatility

Is 76D's price volatile compared to industry and market?
76D volatility
76D Average Weekly Movement	16.6%
Biotechs Industry Average Movement	7.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 76D's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 76D's weekly volatility has decreased from 23% to 17% over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2003	10	Jean-Claude Maurel	www.medesispharma.com

Medesis Pharma S.A. operates as a biopharmaceutical company. The company’s products include NanoLithium (NP03) for the treatment of Alzheimer’s disease; NanosiRNA HD and NanoP42T to treat Huntington’s disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nuclear drugs. It also develops oncology drugs, including NanosiRNA IFNAR and NanoManganese Radiotherapy Glioblastoma.

Medesis Pharma S.A. Fundamentals Summary

How do Medesis Pharma's earnings and revenue compare to its market cap?
76D fundamental statistics
Market cap	€1.75m
Earnings (TTM)	-€3.13m
Revenue (TTM)	€63.64k

27.4x

P/S Ratio

-0.6x

P/E Ratio

Is 76D overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
76D income statement (TTM)
Revenue	€63.64k
Cost of Revenue	€2.13m
Gross Profit	-€2.07m
Other Expenses	€1.07m
Earnings	-€3.13m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.62
Gross Margin	-3,244.94%
Net Profit Margin	-4,924.73%
Debt/Equity Ratio	-64.7%

How did 76D perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/05 17:15
End of Day Share Price	2025/01/03 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medesis Pharma S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Medesis Pharma DB:76D Stock Report